Together, these findings establish HMGB1 as a central regulator of NF-κB activation in cancer, proposing a link between cellular stress and inflammation to MRPs expression-mediating therapy resistance through a convergent HMGB1–NF-κB axis. This evidence concerns the gene HMGB1 and cancer.